Mingjun Li

机构：Chongqing University of Posts and Telecommunications, Hunan University, First Affiliated Hospital of Zhengzhou University · ORCID：0000-0002-3412-025X

发表论文 29 篇 · 总被引 562 次 · h-index 11

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 187)
• Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial (2022 · BMC Medicine · 被引 85)
• Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells (2017 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 被引 37)
• Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6 (2020 · Cancer Cell International · 被引 31)
• CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p (2021 · Cell Cycle · 被引 30)
• Naringenin inhibits osteoclastogenesis through modulation of helper T cells‐secreted IL‐4 (2017 · Journal of Cellular Biochemistry · 被引 22)